AV
AVHHL.US AVITA Medical Inc
- Market cap
- USD 550M
- P/E
- -
- P/B
- 11.03x
- ROE
- -
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is AVHHL.US undervalued?
Graham numberThe Graham number of AVITA Medical Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
AVITA Medical Inc fundamental analysis
No fundamental analysis for AVITA Medical Inc yet.
AVITA Medical Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About AVITA Medical Inc
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can…
Full company profileAVITA Medical Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
AVITA Medical Inc annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.54M | 1.70M | 5.40M | 7.83M | 14.3M | 33.0M | 34.4M | 50.1M | 64.3M | 71.6M | 89.4M |
| Gross Profit | 881K | 703K | 4.21M | 6.01M | 11.3M | 26.9M | 28.4M | 42.4M | 55.2M | 58.8M | 73.9M |
| Operating Income | -16.5M | -13.8M | -36.4M | -36.5M | -42.7M | -25.1M | -27.5M | -42.7M | -56.6M | -42.5M | -24.4M |
| EBITDA | -16.4M | -25.3M | -24.7M | -35.7M | -41.5M | -24.1M | -26.0M | -33.5M | -55.3M | -41.2M | -25.1M |
| Net Income | -15.0M | -23.4M | -24.6M | -35.9M | -42.0M | -25.1M | -26.7M | -35.4M | -61.8M | -48.6M | -32.7M |
| EPS | -2.24 | -2.51 | -0.39 | -1.61 | -2.07 | -1.03 | -1.07 | -1.40 | -2.39 | -1.74 | -1.06 |
| Balance Sheet | |||||||||||
| Total Assets | 10.0M | 31.2M | 25.7M | 25.8M | 82.5M | 116M | 98.3M | 112M | 79.7M | 56.4M | 46.8M |
| Total Liabilities | 3.32M | 5.45M | 4.87M | 4.95M | 10.1M | 11.4M | 13.5M | 62.6M | 75.2M | 73.0M | 77.8M |
| Shareholders' Equity | 6.69M | 25.8M | 20.9M | 20.8M | 72.4M | 105M | 84.7M | 49.1M | 4.50M | -16.7M | -31.0M |
| Cash & Short-term Investments | 4.95M | 20.1M | 20.3M | 20.2M | 73.6M | 85.2M | 79.3M | 89.1M | 35.9M | 18.2M | 10.5M |
| Total Debt | - | 182K | 37.9K | - | 1.92M | 1.64M | 918K | 42.4M | 46.0M | 46.0M | 47.1M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.43M | -13.0M | -19.2M | -27.5M | -22.7M | -18.0M | -19.1M | -38.0M | -48.9M | -31.2M | -19.0M |
| Capital Expenditure | 426K | 365K | 1.45M | 1.51M | 847K | 487K | 525K | 1.45M | 9.33M | 1.74M | 317K |
| Free Cash Flow | -8.85M | -13.3M | -20.7M | -29.6M | -23.6M | -18.5M | -19.6M | -39.5M | -58.3M | -32.9M | -19.4M |
| Ratios | |||||||||||
| ROE | -224.7% | -90.6% | -118.0% | -172.3% | -58.1% | -24.0% | -31.5% | -72.1% | -1,374.6% | - | - |
| ROA | -150.1% | -74.8% | -95.7% | -139.2% | -51.0% | -21.7% | -27.1% | -31.7% | -77.6% | -86.2% | -69.8% |
| Net Profit Margin | -975.0% | -1,370.8% | -456.3% | -458.6% | -294.7% | -76.1% | -77.5% | -70.6% | -96.3% | -67.8% | -36.5% |
| Debt to Equity | - | 0.01x | 0.00x | - | 0.03x | 0.02x | 0.01x | 0.86x | 10.22x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
AVITA Medical Inc dividends
AVITA Medical Inc has not paid dividends in the last 9 fiscal years.
Last stock split: 1:20 on Jun 24, 2020.
Who owns AVITA Medical Inc
- Insiders 0.19%
- Institutions 0.00%
- Public & others 99.81%
- Shares outstanding 157M
- Free float 30.9M
AVITA Medical Inc company profile
- Company name
- AVITA Medical Inc
- Ticker
- AVHHL.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 226
- Fiscal year end
- December
- Address
- 28159 Avenue Stanford, Valencia, CA, United States, 91355
- Phone
- 661 367 9170
- Website
- avitamedical.com
About AVITA Medical Inc
AVITA Medical, Inc., together with its subsidiaries, operates as a therapeutic acute wound care company in the United States, Japan, the European Union, Australia, and the United Kingdom. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds and full-thickness skin defects, as well as for repigmentation of stable depigmented vitiligo lesions. It also provides RECALL autologous cell harvesting device, which can treat areas of up to 1,920 cm2; RECELL autologous cell harvesting device with ease-of-use, an enhanced ease-of-use device that can treat areas of up to 1,920 cm²; and RECELL GO mini autologous cell harvesting device, a line extension of the RECELL GO system to treat smaller wounds up to 480 cm2, as well as RECELL GO autologous cell harvesting device consisting of RECELL GO processing device, which controls and manages the pressure applied to disaggregate the donor skin cells and controls the incubation time of the RECELL Enzyme to optimize cell yield and promote cell viability; and RECELL GO preparation kit, which can treat areas up to 1,920 cm2. In addition, the company sells and distributes PermeaDerm, a biosynthetic wound matrix and Cohealyx, a collagen-based dermal matrix. It serves hospitals, treatment centers, and distributors. The company was formerly known as AVITA Therapeutics, Inc. and changed its name to AVITA Medical, Inc. in December 2020. AVITA Medical, Inc. is headquartered in Valencia, California.
AVITA Medical Inc management
10- Mr. Cary G. VancePresident, CEO & Executive Director · born 1966
- Mr. David O'TooleChief Financial Officer · born 1959
- Ms. Nicole Linda KelseyChief Legal & Compliance Officer & Corporate Secretary · born 1967
- Dr. Niraj Doshi J.D., P.M.P., Ph.D.Senior Vice President of Global Operations
- Dr. Katie Bush Ph.D.Senior Vice President of Scientific & Medical Affairs
- Mr. Ben AtkinsVice President of Investor Relations & Corporate Communications
- Ms. Debbie GarnerSenior Vice President of Global Marketing & Strategy
- Mr. Rob JonesSenior Vice President of Human Resources
- Mr. Ron LagerquistSenior Vice President of Quality Assurance & Regulatory Affairs
- Ms. Robin VanDenburghSenior Vice President of U.S. Commercial Sales